Literature DB >> 3019220

In vitro heterogeneity in human gliomas. Are all transformed cells of glial origin?

A J Franks, H M Burrow.   

Abstract

Primary cultures from 30 human gliomas (26 high grade, 3 low grade, and one oligoastrocytoma) were studied to examine the mixture of cells that make up the outgrowth, and their interactions. GFAP + ve Fibronectin - ve cells had a predominantly process forming (PF) morphology and formed complex networks around explants. Fibronectin + ve GFAP-ve cells had a flattened adherent (FA) morphology, tended to increase in time in culture, in 11 tumours showed a transformed pattern of growth, and may derive from perivascular mesenchyme. Neoplastic glial cells in vivo, or in vitro, may influence the behaviour and nature of other cells in tumour tissue which may be of significance in tumour behaviour and progression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019220

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Spontaneous phenotypic and karyotypic progression in the SV40 transfected cell line SVG during prolonged passage in vitro.

Authors:  P Davey; A M Rauth; L Mason; L Addy
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

2.  Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.

Authors:  P E McKeever; J Varani; S M Papadopoulos; M Wang; J P McCoy
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Glial fibrillary acidic protein, vimentin and fibronectin in primary cultures of human glioma and fetal brain.

Authors:  A Paetau
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

4.  Immunohistochemical localisation of tissue plasminogen activator in human brain tumours.

Authors:  A J Franks; E Ellis
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

5.  Expression of growth factor receptors in human brain tumours.

Authors:  N L Tuzi; D J Venter; S Kumar; S L Staddon; N R Lemoine; W J Gullick
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.